According to a report in the March 27 issue of JAMA.

Based on favorable anecdotal and case statement experience, chelation therapy has evolved in recent decades to include treatment for coronary and peripheral artery disease. Three small clinical trials have assessed the effects of chelation on surrogate outcomes, such as walking distance in patients with claudication and time to exercise-induced ischemia in individuals with coronary disease. These studies didn’t find any proof treatment efficacy but had been underpowered for evaluation of medical events, according to history information in the article. As a consequence, mainstream medical agencies consider the therapeutic worth of chelation for atherosclerotic vascular disease unproven and the use of this therapy potentially dangerous.A Cell Therapy Foundation analysis of current clinical trials points to a crucial need: more federal, private, and philanthropic financing for adult stem cell scientific trials. One gap is usually in the changeover from pre-clinical function to early scientific trials. Sotirios Karathanasis, Vice Head and President of Bioscience in Astra-Zeneca, and person in the advisory table of the Cell Therapy Basis. Headquartered in Indianapolis, IN, the Cell Therapy Base is a not-for-profit company committed to advancing study and the treatment of disease using adult stem cells. In america, only a handful of such clinical trials have reached Phase III, the stage to submission for regulatory approval prior.

Other entries from category "neurosurgery":

Random entries